: What to expect after the Oxford-AstraZeneca COVID-19 vaccine news
U.K.-based drugmaker AstraZeneca said on Monday that the coronavirus vaccine it is developing with the University of Oxford had shown an average efficacy of 70% in the Phase 3 trials.
